CN1268361C - Chinese traditional medicine composition for treating cardiovascular and cerebrovascular diseases - Google Patents
Chinese traditional medicine composition for treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN1268361C CN1268361C CN 200310117309 CN200310117309A CN1268361C CN 1268361 C CN1268361 C CN 1268361C CN 200310117309 CN200310117309 CN 200310117309 CN 200310117309 A CN200310117309 A CN 200310117309A CN 1268361 C CN1268361 C CN 1268361C
- Authority
- CN
- China
- Prior art keywords
- paeoniae rubra
- radix paeoniae
- radix
- injection
- radix puerariae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 6
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 239000003978 infusion fluid Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 5
- 230000036770 blood supply Effects 0.000 abstract description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 238000012795 verification Methods 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000008215 water for injection Substances 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 239000003708 ampul Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000007789 sealing Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 206010053567 Coagulopathies Diseases 0.000 description 5
- 239000009277 Panax notoginseng extract Substances 0.000 description 5
- 230000003727 cerebral blood flow Effects 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- 241000219780 Pueraria Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- -1 lactone glycoside Chemical class 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 210000004298 cerebral vein Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000009835 oxypaeoniflora Substances 0.000 description 1
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 1
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicine for treating cardiovascular and cerebrovascular diseases, and a preparation thereof. The medicine is composed of red peony root and kudzuvine root. By the experimental verification of medicine effect, the medicine has the obvious efficiency of improving cardiovascular and cerebrovascular blood-supply shortage, resisting thrombosis, etc.
Description
Affiliated field
The present invention relates to a kind of medicine and preparation thereof for the treatment of cardiovascular and cerebrovascular disease, belong to medical pharmaceutical field, particularly belong to the Chinese medicine antithrombotic, improve cardiovascular and cerebrovascular vessel blood supply insufficiency pharmaceutical technology field.
Background technology
Radix Puerariae is widely used as food for a long time, is medically doing the clearing away heat and expelling pathogen in the exterior agent, and the treatment flu finds that now Radix Puerariae contains various active compositions such as flavone, has effects such as the cerebral vascular resistance of reduction, cerebral blood flow increasing amount, lax nerve, allaying tiredness.Wherein Radix Puerariae flavone has a stronger inhibitory action to thrombin such as thrombin and partial prothrombinase are former, also has the effect that thrombus in vivo forms that suppresses.Its main functional component puerarin can promote the normal brain activity circulation and improve the local microcirculation obstacle, increases the amplitude of blood capillary motion, improves regional blood flow.
The main effective ingredient of Radix Paeoniae Rubra is paeoniflorin (Paeoniforin), peony lactone glycoside (Albiforin), hydroxypaeoniflorin (Oxy paeoniflorin), benzoylpaeoniflorin monoterpene glycoside compounds such as (Benzoyl paeoniflorin) is called for short the Radix Puerariae Radix Paeoniae Rubra extract.The modern plants chemistry thinks that Radix Paeoniae Alba total glycosides is the active component in the Radix Paeoniae, mainly is present in the root bark portion of Radix Paeoniae.Traditional medicine thinks, Radix Paeoniae Rubra can clearing away heat and cooling blood, and eliminating stasis to stop pain clinically, is diseases such as monarch drug prescription therapeutic ischemic angiocardiopathy and cerebrovascular with Radix Paeoniae Rubra or with Radix Paeoniae Rubra.
Theory of Chinese medical science thinks that two medicines mutually 5 have to rise to have and rush down, and has field headquarters blood, removes the function of arthralgia due to stagnation of blood, the meridian dredging.Modern effect experiment proves, two medicines 5 have mutual synergic effect mutually, and the preparation made of two flavor medicines has significant cardiovascular and cerebrovascular vessel blood supply insufficiency and the antithrombotic effect improved thus.
Summary of the invention
The invention discloses a kind of modern compound preparation for the treatment of cardiovascular and cerebrovascular disease, said preparation is made up of Radix Paeoniae Rubra and Radix Puerariae two flavor medicines, and its dosage form can be a solid preparation, also can be liquid preparation.Solid preparation comprises tablet, slow releasing tablet, capsule, slow releasing capsule, soft capsule and drop pill etc.Liquid preparation can be aqueous injection, injectable powder, infusion solution and fat milk injection.Various dosage forms are to make with conventional method, and wherein Radix Paeoniae Rubra extract and Radix Puerariae extract existence are solid, shaped or liquid, and administering mode is oral, intravenous or intramuscular injection
The solid constituent of Radix Puerariae Radix Paeoniae preparation is made up of Radix Puerariae extract and Radix Paeoniae Rubra extract and pharmaceutic adjuvant, two flavor medicine weight ratios are: Radix Paeoniae Rubra 0.5-0.9 part, Radix Puerariae 0.1-0.5 part also can be Radix Paeoniae Rubra 0.1-0.5 part, Radix Puerariae 0.5-0.9 part, such as: 1 part of Radix Puerariae, 2 parts of 2 parts of Radix Paeoniae Rubra or Radix Puerariaes, 1 part of Radix Paeoniae Rubra also can be 1 part of a Radix Puerariae, 1 part of Radix Paeoniae Rubra, various preparations are all made according to common process.
Below by embodiment modern compound preparation of cardiovascular medicament with antithrombotic acitivity of the present invention and preparation method thereof is described further.
Embodiment 1:
Preparation Radix Puerariae Radix Paeoniae Rubra extract aqueous injection, prescription ratio: 1 part of Radix Puerariae, 2 parts of Radix Paeoniae Rubra.
1kg is dissolved in the 100L water for injection with the Radix Puerariae Radix Paeoniae Rubra extract, is made into 10mg/ml, regulates PH to 6.0.After the microporous filter membrane ultrafiltration, replenish water for injection to ormal weight, fill is in ampoule bottle, and the sealing by fusing sterilization through after the assay was approved, is packed promptly.
Embodiment 2:
Preparation Radix Puerariae Radix Paeoniae Rubra extract aqueous injection, prescription ratio: 2 parts of Radix Puerariaes, 1 part of Radix Paeoniae Rubra.
1kg is dissolved in the 100L water for injection with the Radix Puerariae Radix Paeoniae Rubra extract, is made into 10mg/ml, regulates PH to 6.0.After the microporous filter membrane ultrafiltration, replenish water for injection to ormal weight, fill is in ampoule bottle, and the sealing by fusing sterilization through after the assay was approved, is packed promptly.
Embodiment 3:
Preparation Radix Puerariae Radix Paeoniae Rubra extract aqueous injection, prescription ratio: 1 part of Radix Puerariae, 1 part of Radix Paeoniae Rubra.
1kg is dissolved in the 100L water for injection with the Radix Puerariae Radix Paeoniae Rubra extract, is made into 10mg/ml, regulates PH to 6.0.After the microporous filter membrane ultrafiltration, replenish water for injection to ormal weight, fill is in ampoule bottle, and the sealing by fusing sterilization through after the assay was approved, is packed promptly.
Embodiment 4
Preparation Radix Puerariae Radix Paeoniae Rubra injectable powder, prescription ratio: 1 part of Radix Puerariae, 2 parts of Radix Paeoniae Rubra.。
Radix Puerariae Radix Paeoniae Rubra extract 1kg is dissolved in an amount of 100L water for injection, the pharmaceutic adjuvant that adds metering, regulate PH to 6.0, after the microporous filter membrane ultrafiltration, vacuum drying gets Radix Puerariae Radix Paeoniae Rubra extract aseptic powder, and aseptic powder is sub-packed in the cillin bottle, make every bottle and contain Radix Puerariae Radix Paeoniae Rubra extract aseptic powder 100mg, three specifications of 150mg, 200mg, roll lid, through after the assay was approved, packing promptly.
Embodiment 5
Preparation Radix Puerariae Radix Paeoniae Rubra lyophilized injectable powder, prescription ratio: 2 parts of Radix Puerariaes, 1 part of Radix Paeoniae Rubra.
With Radix Puerariae Radix Paeoniae Rubra extract 1kg, after the dissolving of 5 times of amount water for injection, add the injection water solublity pharmaceutic adjuvant of metering, regulate PH to 6.0, filter, be loaded in the ampoule bottle, every 10ml, after lyophilization, sealing by fusing, after the assay was approved, packing is promptly.
Embodiment 6
Preparation Radix Puerariae Radix Paeoniae Rubra lyophilized injectable powder, prescription ratio: 1 part of Radix Puerariae, 1 part of Radix Paeoniae Rubra.
With Radix Puerariae Radix Paeoniae Rubra extract 1kg, after the dissolving of 5 times of amount water for injection, add the injection water solublity pharmaceutic adjuvant of metering, regulate PH to 6.0, filter, be loaded in the ampoule bottle, every 10ml, after lyophilization, sealing by fusing, after the assay was approved, packing is promptly.
Embodiment 7
Preparation Radix Puerariae Radix Paeoniae Rubra lyophilized injectable powder, prescription ratio: 1 part of Radix Puerariae, 2 parts of Radix Paeoniae Rubra.
With Radix Puerariae Radix Paeoniae Rubra extract 1kg, after the dissolving of 5 times of amount water for injection, add the injection water solublity pharmaceutic adjuvant of metering, regulate PH to 6.0, filter, be loaded in the ampoule bottle, every 10ml, after lyophilization, sealing by fusing, after the assay was approved, packing is promptly.
Embodiment 8
Preparation Radix Puerariae Radix Paeoniae Rubra lipomul, prescription ratio: 1 part of Radix Puerariae, 2 parts of Radix Paeoniae Rubra.
With Radix Puerariae Radix Paeoniae Rubra extract 1kg, be dissolved in the 100L injection fat solvent (forming) by water for injection and emulsifying agent, be made into the solution of 10mg/ml, regulate PH to 6.0.After the microporous filter membrane ultrafiltration, be sub-packed in 2ml, the 5ml ampoule, after the assay was approved, packing is promptly.
Embodiment 9
Preparation Radix Puerariae Radix Paeoniae Rubra lipomul, prescription ratio: 2 parts of Radix Puerariaes, 1 part of Radix Paeoniae Rubra.
With Radix Puerariae Radix Paeoniae Rubra extract 1kg, be dissolved in the 100L injection fat solvent (forming) by water for injection and emulsifying agent, be made into the solution of 10mg/ml, regulate PH to 6.0.After the microporous filter membrane ultrafiltration, be sub-packed in 2ml, the 5ml ampoule, after the assay was approved, packing is promptly.
The pharmacological effect experiment
Experiment 1, Radix Puerariae Radix Paeoniae Rubra extract are to the thrombotic influence of rats in vitro
Experiment material
1. medicine: Radix Puerariae Radix Paeoniae Rubra extract powder pin: 100mg/ props up; The injection XUESHUANTONG: 50mg/ props up.
2. animal: 40 of healthy male Wistar rats, body weight 200.72 ± 9.0g.
Experimental technique
40 rats are divided into 4 groups (10 every group) at random: 1. matched group (0.9% sodium chloride injection, 5.0ml/kg), 2. Radix Puerariae Radix Paeoniae Rubra powder pin 20mg/kg dosage group, 3. Radix Puerariae Radix Paeoniae Rubra powder pin 10mg/kg dosage group, 4. injection XUESHUANTONG 20mg/kg dosage group.Each treated animal by described dosage with the injection volume of 5.0ml/kg through the tail vein injection administration, once a day, successive administration 3 days, 30min after the last administration with pentobarbital sodium (30.0mg/kg) anesthesia, is used for external thrombus from abdominal aortic blood 2ml and forms and measure.
External thrombus forms to be measured: according to the Chandler in vitro method, at once blood is injected in the rotating ring, the blood volume of injection is full of rotating ring below 1/2, rapidly sealing, put on the thrombosis instrument, rotation 10min, inclining thrombosis, the normal saline washing, measure length, the weighing weight in wet base is put 80 ℃ of baking oven 3h with the thrombosis bar, claims its dry weight after the constant weight.
Experimental result:
Table 1. Radix Puerariae Radix Paeoniae Rubra extract is to the thrombotic influence of rats in vitro (X ± SD)
| Group | Dosage (/kg) | Number of animals | Thrombosis | ||
| Length (mm) | Weight in wet base (mg) | Dry weight (mg) | |||
| Matched group | 10 | 21.1±1.8 | 150.4±10.0 | 26.7±1.7 | |
| The injection XUESHUANTONG | 20mg | 10 | 16.1±2.0 | 130.6±16.3 | 20.4±3.7 |
| Radix Puerariae Radix Paeoniae Rubra extract powder pin | 10mg | 10 | 20.9±1.5 | 134.1±12.0 | 23.3±6.1 |
| Radix Puerariae Radix Paeoniae Rubra extract powder pin | 20mg | 10 | 16.6±3.1 | 130.7±20.4 | 19.3±4.5 |
Annotate: compare P＜0.01 with matched group
By table 1 as seen, compare with matched group, the thrombosis length of Radix Puerariae Radix Paeoniae Rubra powder pin 20mg/kg and 10mg/kg dosage group all obviously shortens (P＜0.01), and wet weight of thrombus and dry weight all obviously alleviate (P＜0.01), and the thrombosis dry weight has the trend of alleviating; The thrombosis dry weight of injection XUESHUANTONG group obviously alleviates (P＜0.05), and thrombosis length has shortening trend, and wet weight of thrombus has the trend of alleviating.Show that Radix Puerariae Radix Paeoniae Rubra powder needle set has the effect that suppresses thrombosis, blood viscosity lowering, to compare drug effect suitable with XUESHUANTONG.
Experiment 2: the Radix Puerariae Radix Paeoniae Rubra extract is to the influence of clotting time of mice
40 of kunming mices are divided into 5 groups at random, each treated animal by described dosage with the injection volume of 5.0ml/kg through the tail vein injection administration, once a day, successive administration 3 days, behind the 1h, abdominal aortic blood is used the determination of tube method clotting time after the last administration.The result: three kinds of dosage all obviously prolong the clotting time of mice.
Experimental result:
Table 2 Radix Puerariae Radix Paeoniae Rubra extract is to the influence of clotting time of mice (n=10, x ± s)
| Group | Dosage (mg/kg) | Clotting time (s) |
| Normal saline Radix Puerariae Radix Paeoniae Alba extract (greatly) Radix Puerariae Radix Paeoniae Alba extract (in) Radix Puerariae Radix Paeoniae Alba extract (little) aspirin | Deng capacity 20 10 5 10 | 57.1±9.8 69.8±12.2 63.5±12.0 57.6±11.7 67.1±10.6 |
Compare P＜0.01 with the normal saline group
Experiment 3: Radix Puerariae Radix Paeoniae Rubra injection is to Medulla Leporis seu Oryctolagi circulation and the metabolic influence of brain
1.1 animal: 32 of new zealand rabbits, body weight 2.0～3.0kg, male and female dual-purpose.
1.2 medicine: Radix Puerariae Radix Paeoniae Rubra injection (self-control) is made into 10mg/ml.
1.3 instrument: MF-1200 type electromagnetic flowmeter, STAT-PROFILE-5 type electrolyte analyser.
Experimental technique:
2.1 animal preparation: animal via urethane (1.0g/kg) auricular vein injecting anesthetic, the circulation of qi promoting cannula separates two side femoral artery, sidelights record blood pressure, opposite side extracts arterial blood.Separate a side common carotid artery and internal carotid artery and external carotid artery simultaneously, ligation external carotid artery and branch thereof are in order to laying the electromagnetic flowmeter probe at the common carotid artery place.The rabbit head is fixed on the stereotaxic instrument, cuts cranium item skin, expose posterior lambdoid suture place, boring is in order to extracting cerebral veins, venae cerebri blood above torcular.
2.2 animal grouping: animal is divided into 4 groups at random, i.e. the heavy dose of group of Radix Puerariae Radix Paeoniae Rubra (44mg/kg), Radix Puerariae Radix Paeoniae Rubra small dose group (22mg/kg), nimodipine group (3 μ g/kg) and normal saline matched group.8 of every treated animals.The auricular vein drug administration by injection.
2.3 hemodynamics is measured: the left side femoral arteriography is connected in AP-621G carrier amplifier recording blood pressure through pressure transducer, with the AT-611G Cardiotacs heart rate is carried out the integration record.
2.4 ICAF quantitative determination: use the method for measuring the ICAF amount and judge cerebral blood flow (CBF).The probe that bore is suitable places on the side common carotid artery, and is connected in MF-1200 type electromagnetic flowmeter, judges CBF by the ICAF amount.
Experimental result proves, Radix Puerariae Radix Paeoniae Rubra injection can the cerebral blood flow increasing amount, improves brain oxygen consumption and glucose uptake amount, illustrates that it has the cerebral circulation of improvement and the metabolic dual function of brain.
Claims (2)
1, a kind of solid preparation of cardiovascular and cerebrovascular disease or modern compound preparation of liquid preparation form for the treatment of is characterized in that being made by the crude drug of pharmaceutic adjuvant and following weight fraction:
Radix Paeoniae Rubra 1-2 part
Radix Puerariae 1-2 part.
2, according to the preparation of claim 1, described solid preparation form is tablet, slow releasing tablet, capsule, slow releasing capsule, soft capsule or drop pill, and described liquid preparation form is aqueous injection, injectable powder, infusion solution or fat milk injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310117309 CN1268361C (en) | 2003-12-08 | 2003-12-08 | Chinese traditional medicine composition for treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310117309 CN1268361C (en) | 2003-12-08 | 2003-12-08 | Chinese traditional medicine composition for treating cardiovascular and cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1546137A CN1546137A (en) | 2004-11-17 |
| CN1268361C true CN1268361C (en) | 2006-08-09 |
Family
ID=34337766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310117309 Expired - Lifetime CN1268361C (en) | 2003-12-08 | 2003-12-08 | Chinese traditional medicine composition for treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1268361C (en) |
-
2003
- 2003-12-08 CN CN 200310117309 patent/CN1268361C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1546137A (en) | 2004-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1955170A (en) | Class I tanshinone II A derivative and its application in pharmaceutic | |
| CN1762401A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1943757A (en) | A Chinese traditional medicinal composition for treatment of hemicrania and its preparation method | |
| CN101467967B (en) | Double-element solution type preparation for intravenous injection and intracerebral injection | |
| CN1268361C (en) | Chinese traditional medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN101181285A (en) | Application of astragaloside IV in the preparation of medicament for curing nervus retrogression disease | |
| CN1846734A (en) | Prince's-feather prepn and its prepn process and application | |
| CN1278433A (en) | Thrombolytic medicine and its preparation and use | |
| CN1899509A (en) | Chinese medicine injection for supplementing qi and recovering pulse and its preparing method | |
| CN1565465A (en) | Injection preparation containing breviscapine active component and its preparation method | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1899352A (en) | Chinese medicine effective part composition for supplementing qi and recovering pulse | |
| CN102716231B (en) | A kind of Chinese medicine composition and application thereof for the treatment of brain injury and cerebral edema | |
| CN101966196A (en) | Formula of catalpol-puerarin injection and powder and preparation method | |
| CN1879714A (en) | A Chinese medicinal composition for treating thrombus | |
| CN101559037B (en) | Binary solution type preparation for intravenous injection and intracerebral injection | |
| CN107998117B (en) | A kind of combination of oral medication for treating capillary leak syndrome | |
| CN1733013A (en) | Novel route for administering hairy holly injection and preparation process thereof | |
| CN104825627B (en) | It is a kind of to treat anginal oral gel preparation and preparation method thereof | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1281212C (en) | General saponin of stem and leaf of American ginseng in Application of preparing medication for treating mycoarditis | |
| CN107951885B (en) | A kind of combination of oral medication for treating capillary leak syndrome | |
| CN1857293A (en) | Medicine composition containing wild astragaloside and paeoniforin | |
| CN1308008C (en) | Pharmaceutical composition for treaitng coronary heart disease | |
| CN1552723A (en) | Liaodong oak leaf saponin and its medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DD01 | Delivery of document by public notice |
Addressee: Zhang Wenfang Document name: Written notice of preliminary examination of application for patent for invention |
|
| DD01 | Delivery of document by public notice |
Addressee: Zhang Wenfang Document name: Written notice of preliminary examination of application for patent for invention |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BIOVALLEY TECHNOLOGIES(SHENZHEN)CO.,LTD. Free format text: FORMER OWNER: ZHANG WENFANG Effective date: 20060707 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20060707 Address after: 518026, Futian District, Yitian Road, Jiangsu building, block A, building 34, Shenzhen biological Valley Science and Technology Co., Ltd., Shenzhen Patentee after: Shenzhen Biovalley Technology Co.,Ltd. Address before: 100089 Beijing city Haidian District North wa Road Lane South Ditch No. 8 smartfortune mansion room 801 Patentee before: Zhang Wenfang |
|
| C56 | Change in the name or address of the patentee |
Owner name: SHENZHEN CITY JINSHA JIANG INVESTMENT CO., LTD. Free format text: FORMER NAME: SHENZHEN CITY BIOVALLEY TECHNOLOGY CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 518026, Futian District, Yitian Road, Jiangsu building, block A, building 34, Shenzhen biological Valley Science and Technology Co., Ltd., Shenzhen Patentee after: Shenzhen Jinshajiang Investment Co.,Ltd. Address before: 518026, Futian District, Yitian Road, Jiangsu building, block A, building 34, Shenzhen biological Valley Science and Technology Co., Ltd., Shenzhen Patentee before: Shenzhen Biovalley Technology Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: YUNNAN BIOVALLEY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHENZHEN JINSHAJIANG INVESTMENT CO., LTD. Effective date: 20130524 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 518026 SHENZHEN, GUANGDONG PROVINCE TO: 650224 KUNMING, YUNNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130524 Address after: 650224 University Science Park, hi tech Industrial Development Zone, Yunnan, Kunming Patentee after: YUNNAN BIOVALLEY PHARMACEUTICAL Co.,Ltd. Address before: 518026, Guangdong, Shenzhen, Yitian Road, Jiangsu building, block A, building 34, Shenzhen Jinsha River Investment Co., Ltd. Futian District Patentee before: Shenzhen Jinshajiang Investment Co.,Ltd. |
|
| DD01 | Delivery of document by public notice |
Addressee: Lin Gufeng Document name: Notification of Passing Examination on Formalities |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060809 |